Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Boston: Superluminal Medicines, a drug discovery company integrating AI/ML, protein dynamics, and structural biology to ...

Superluminal partners with Eli Lilly to develop AI-driven small molecule therapies targeting GPCRs for obesity and ...

Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs ...

The deal allows Eli Lilly and Company (NYSE:LLY) to have exclusive rights to develop and commercialize drug candidates ...

Eli Lilly (LLY) has signed a $1.3 billion deal with privately held biotechnology firm Superluminal Medicines that will see ...

Superluminal Medicines, a healthcare company integrating AI/ML, announced partnership with Eli Lilly (NYSE:LLY) to advance ...

Eli Lilly and Company (NYSE:LLY) is one of the stocks Jim Cramer recently discussed. When a caller inquired about the company ...

Eli Lilly has a market value of more than $420 billion, and sells blockbuster treatments for diabetes and cancer. It's already begun to invest in a host of projects focused on AI.

On August 8, 2025, JPMorgan maintained its ‘Overweight’ rating on Eli Lilly and Company (NYSE:LLY) with a $1,100 price target ...

AI is thus poised to radically transform the pharmaceutical industry. Two of the leading players in this field are Eli Lilly (LLY 0.84%) and GSK (GSK -0.68%), both of which have invested heavily ...